3 Forgings and Defence Systems Maker, Footwear Retailer and Fermentation Based Pharma Ingredients Maker Stocks With a Strong Future Roadmap: Bharat Forge, Metro Brands and Concord Biotech

Forging major, footwear and fermentation stocks let investors follow companies that serve a growing part of the Indian economy. Bharat Forge, Metro Brands and Concord Biotech cover a forgings and defence systems maker, a footwear retailer and a fermentation based pharma ingredients maker.

This list covers three forging major, footwear and fermentation stocks with complete current figures: Bharat Forge, Metro Brands and Concord Biotech. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Forging Major, Footwear and Fermentation Stocks?

Forging major, footwear and fermentation stocks are listed companies that produce forged and machined parts for vehicles, industry and defence, run branded footwear stores across many cities, and make fermentation based active pharmaceutical ingredients. Their earnings depend on vehicle and defence orders, consumer spending and pharma sourcing.

Forging Major, Footwear and Fermentation Stocks at a Glance

On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing forging major, footwear and fermentation stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Forging Major, Footwear and Fermentation Stocks Have a Strong Roadmap in India?

Forging major, footwear and fermentation stocks have a strong roadmap in India because strong defence indigenisation, rising demand for branded footwear and growing global demand for specialty pharma ingredients keep widening the market for these companies.

• Forgings. Vehicles and defence need strong parts.
• Footwear. Shoppers upgrade to branded footwear.
• Pharma ingredients. Drug makers need reliable fermentation inputs.

Why Bharat Forge Features Among These Forging Major, Footwear and Fermentation Stocks

Among the forging major, footwear and fermentation stocks on this list, Bharat Forge is a Pune-based maker of forgings, axles and chassis components for automotive and industrial customers, and it has a growing defence and aerospace business that includes artillery systems and components.

In the June 2026 quarter, revenue grew 18.7% year on year to Rs 4,697 crore. Revenue rose from Rs 10,657 crore in FY22 to Rs 17,010 crore in FY26, a compound annual growth rate of 12.4%.

Net profit grew from Rs 508 crore in FY23 to Rs 1,089 crore in FY26, which works out to a compound annual growth rate of 28.9%. The company has a return on equity of 11.3%, a debt to equity ratio of 0.76 and a market capitalisation of Rs 87,540 crore. The stock trades at a P/E of 122.4, above the industry P/E of 50.7.

Roadmap: The company is widening its mix beyond automotive into defence, aerospace and industrial products, where programmes run for many years. Its forging expertise and global customer base support a range of applications.

What to watch: Check order inflow in defence and aerospace and the share of non-automotive sales.

Why Metro Brands Features Among These Forging Major, Footwear and Fermentation Stocks

Among the auto and defence forging, shoe store and drug input shares on this list, Metro Brands is a Mumbai-based footwear retailer operating the Metro, Mochi, Walkway and Crocs outlets, and also selling through online channels and select partner brands.

The company has a return on equity of 19.8%, a debt to equity ratio of 0.76 and a market capitalisation of Rs 23,316 crore. The stock trades at a P/E of 55.4, above the industry P/E of 37.0.

Revenue rose from Rs 1,402 crore in FY22 to Rs 2,968 crore in FY26, a compound annual growth rate of 20.6%. Net profit grew from Rs 213 crore in FY22 to Rs 416 crore in FY26, which works out to a compound annual growth rate of 18.2%.

Roadmap: The company is opening new stores across cities and adding premium and international brands to its range. An omni-channel presence helps it reach a wider set of shoppers.

What to watch: Track store openings, premium brand share and online sales.

Why Concord Biotech Features Among These Forging Major, Footwear and Fermentation Stocks

Among the three companies on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.

Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%.

In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.

Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.

What to watch: Monitor the pace of new product introductions and the contribution from formulations.

Bharat Forge vs Metro Brands vs Concord Biotech on Key Financials

The table below sets the three forging major, footwear and fermentation stocks side by side on revenue, profit and margin, using reported figures.

Metro Brands posts the highest return on equity in this group at 19.8%. Bharat Forge has the largest FY26 revenue at Rs 17,010 crore, and Metro Brands shows the fastest revenue growth with a 20.6% compound annual rate. A useful habit with forging major, footwear and fermentation stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Forging Major, Footwear and Fermentation Stocks

Every theme carries risks that deserve a check before any decision. For these forging major, footwear and fermentation stocks, the main points are:

• Order timing. Defence and space orders can shift between periods.
• Footfall and spending. Store sales follow consumer mood and seasons.
• Regulatory approvals. Plant inspections and approvals can affect supplies.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter forging major, footwear and fermentation stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Forging Major, Footwear and Fermentation Stocks

Forging major, footwear and fermentation stocks reward investors who follow demand trends, order books and margins together. Bharat Forge, Metro Brands and Concord Biotech each have a clear plan to grow. Based on the 11 November 2026 close, Bharat Forge trades at Rs 1,748.6, Metro Brands at Rs 838.05 and Concord Biotech at Rs 597.2.

Download the Univest iOS App or Univest Android App to track forging major, footwear and fermentation stocks, set price alerts and get research-backed stock ideas.

What are forging major, footwear and fermentation stocks?

Ans. Forging major, footwear and fermentation stocks are listed companies that produce forged and machined parts for vehicles, industry and defence, run branded footwear stores across many cities, and make fermentation based active pharmaceutical ingredients. Their earnings depend on vehicle and defence orders, consumer spending and pharma sourcing. This list looks at three of them, Bharat Forge, Metro Brands and Concord Biotech, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which forging major, footwear and fermentation stocks are covered in this list?

Ans. This list covers Bharat Forge, Metro Brands and Concord Biotech. Based on the 11 November 2026 close, Bharat Forge traded at Rs 1,748.6, Metro Brands at Rs 838.05 and Concord Biotech at Rs 597.2. Their return on equity ranges from 11.3% to 19.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 20.6%.

Why do forging major, footwear and fermentation stocks have a strong future roadmap in India?

Ans. Forging major, footwear and fermentation stocks have a strong roadmap in India because strong defence indigenisation, rising demand for branded footwear and growing global demand for specialty pharma ingredients keep widening the market for these companies. The main drivers are as follows. Forgings. Vehicles and defence need strong parts. Footwear. Shoppers upgrade to branded footwear. Pharma ingredients. Drug makers need reliable fermentation inputs. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Bharat Forge performed financially?

Ans. Revenue rose from Rs 10,657 crore in FY22 to Rs 17,010 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 508 crore in FY23 to Rs 1,089 crore in FY26, which works out to a compound annual growth rate of 28.9%. In the June 2026 quarter, revenue grew 18.7% year on year to Rs 4,697 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.76 and a market capitalisation of Rs 87,540 crore. The stock trades at a P/E of 122.4, above the industry P/E of 50.7. Looking ahead, the company is widening its mix beyond automotive into defence, aerospace and industrial products, where programmes run for many years. Its forging expertise and global customer base support a range of applications.

How has Metro Brands performed financially?

Ans. Revenue rose from Rs 1,402 crore in FY22 to Rs 2,968 crore in FY26, a compound annual growth rate of 20.6%. Net profit grew from Rs 213 crore in FY22 to Rs 416 crore in FY26, which works out to a compound annual growth rate of 18.2%. The company has a return on equity of 19.8%, a debt to equity ratio of 0.76 and a market capitalisation of Rs 23,316 crore. The stock trades at a P/E of 55.4, above the industry P/E of 37.0. Looking ahead, the company is opening new stores across cities and adding premium and international brands to its range. An omni-channel presence helps it reach a wider set of shoppers.

How has Concord Biotech performed financially?

Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.

What risks should investors check before buying forging major, footwear and fermentation stocks?

Ans. Investors should check a few risks before buying forging major, footwear and fermentation stocks. Order timing. Defence and space orders can shift between periods. Footfall and spending. Store sales follow consumer mood and seasons. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of forging major, footwear and fermentation stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.